These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9720394)

  • 1. [Decreased content of non-heme iron in the blood of patients with peripheral tapetoretinal abiotrophy].
    Pozdeev NV; Volkova MV; Efimova MG; Astakhov IuS; Etingof RN
    Vestn Oftalmol; 1998; 114(3):25-6. PubMed ID: 9720394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment results using the preparation ENKAD in patients with peripheral tapetoretinal abiotrophy].
    Katsnel'son LA; Maslova-Khoroshilova IP; Eliseeva RF; Dnestrova GI
    Vestn Oftalmol; 1988; 104(6):54-61. PubMed ID: 3242209
    [No Abstract]   [Full Text] [Related]  

  • 3. [Changes in the blood uric acid levels in patients with retinitis pigmentosa and in rats with hereditary retinal degeneration].
    Chusova GG; Ostapenko IA; Shabanova ME; Eliseeva RF
    Biull Eksp Biol Med; 1982 Nov; 94(11):21-3. PubMed ID: 7150729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of the use of vasoactive preparation pikamilon in pigmented retinal abiotrophy].
    Davydova GA; Mukha AI
    Vestn Oftalmol; 1995; 111(3):20-2. PubMed ID: 7483195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Time course of visual functions in patients with pigmentary retinal degeneration after surgical treatment with biomaterial "Alloplant"].
    Galimova VU
    Vestn Oftalmol; 2001; 117(3):20-3. PubMed ID: 11521429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations.
    Sandberg MA; Rosner B; Weigel-DiFranco C; Dryja TP; Berson EL
    Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1298-304. PubMed ID: 17325176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between visual acuity and central retinal thickness in retinitis pigmentosa.
    Sandberg MA; Brockhurst RJ; Gaudio AR; Berson EL
    Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3349-54. PubMed ID: 16123439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Time course of bioelectrical activity of retina in patients with pigmented abiotrophy treated by deoxinate].
    Tsapenko IV; Riabina MV; Zueva MV; Eliseeva RF; Katsnel'son LA
    Vestn Oftalmol; 1999; 115(4):24-6. PubMed ID: 10523963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain iron homeostasis.
    Moos T
    Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentric retinitis pigmentosa: clinicopathologic correlations.
    Milam AH; De Castro EB; Smith JE; Tang WX; John SK; Gorin MB; Stone EM; Aguirre GD; Jacobson SG
    Exp Eye Res; 2001 Oct; 73(4):493-508. PubMed ID: 11825021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa.
    Hoffman DR; Locke KG; Wheaton DH; Fish GE; Spencer R; Birch DG
    Am J Ophthalmol; 2004 Apr; 137(4):704-18. PubMed ID: 15059710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron homeostasis in relapsing steroid-sensitive nephrotic syndrome of childhood.
    Kemper MJ; Bello AB; Altrogge H; Timmermann K; Ludwig K; Müller-Wiefel DE
    Clin Nephrol; 1999 Jul; 52(1):25-9. PubMed ID: 10442492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathological changes in the eyeball in tapetoretinal abiotrophy].
    Katsnel'son LA; Ioshin IE; Eliseeva RF; Valishanskaia TI; Rozenfel'd IA; Zueva MV; Tsapenko IV
    Vestn Oftalmol; 1991; 107(1):50-4. PubMed ID: 2035207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina].
    Khvatova AV; Khlebnikova OV; Meshkova GI; Tarasenkov AO; Shchuvatova EL; Stromova OV
    Vestn Oftalmol; 2005; 121(2):19-21. PubMed ID: 15881150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration in iron metabolism during retinal degeneration in rd10 mouse.
    Deleon E; Lederman M; Berenstein E; Meir T; Chevion M; Chowers I
    Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1360-5. PubMed ID: 18997094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Behavior of serum iron levels and total iron-binding capacity following gastrectomy].
    Schröder H; Winnefeld K; Splinter K
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(3):118-23. PubMed ID: 6499725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Iron metabolism in retinitis pigmentosa].
    Hermel B; Kardaszewicz E; Rodkiewicz M
    Pol Tyg Lek; 1981 Jan; 36(1):13-4. PubMed ID: 7243662
    [No Abstract]   [Full Text] [Related]  

  • 18. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod dystrophy.
    Birch DG; Anderson JL; Fish GE
    Ophthalmology; 1999 Feb; 106(2):258-68. PubMed ID: 9951474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
    Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
    Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron-binding antioxidant capacity is impaired in diabetes mellitus.
    Van Campenhout A; Van Campenhout C; Lagrou AR; Moorkens G; De Block C; Manuel-y-Keenoy B
    Free Radic Biol Med; 2006 May; 40(10):1749-55. PubMed ID: 16678014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.